Primary outcome was average pain intensity measured at day 7 ( NRS , 0 to 10 ) ; secondary outcomes were analgesic consumption ( oral morphine equivalents ) , fatigue and appetite loss ( European Organisation for Research and Treatment of Cancer-Quality of Life Questionnaire C30 , 0 to 100 ) , and patient satisfaction ( NRS , 0 to 10 ) .